Vital Signs - Human Growth Hormone - A Multifaceted Paradigm for Specialty Pharma

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on October 1, 2007, provides a strategic overview of issues and opportunities surrounding human growth hormone. Additionally, a company spotlight is provided for BioMS Medical, a biotechnology company with a core interest in the treatment of multiple sclerosis. Reimbursement and regulatory news from the FDA is also provided for the week of September 17 - September 21, 2007.

Table of Contents

Vital Signs - Human Growth Hormone - A Multifaceted Paradigm for Specialty PharmaVital Signs: 1 October 2007This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.